Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Tuesday, May 5, 2015

Newest Hepatitis C Drug Without Interferon Achieves 93 Percent Cure Rate

Researchers unsure whether the new hepatitis C drug’s entry into the U.S. market will drive down prices.

Another pharmaceutical company appears headed to market with a drug that cures hepatitis C genotype 1, without interferon and ribavirin, in just 12 weeks.

Research published today in The Journal of the American Medical Association (JAMA) showed a combination of Bristol-Myers Squibb drugs daclatasvir, asunaprevir, and beclabuvir cured hepatitis C in 93 percent of 112 study participants with cirrhosis who had not previously been treated.

The drug combination also eliminated the hepatitis virus in 87 percent of 90 participants who had treatment in the past that didn’t work. When ribavirin was added, the success rate climbed to 93 percent.

Read more...

No comments:

Post a Comment